NCT05381753View on ClinicalTrials.gov

Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World

CompletedOBSERVATIONAL
Enrollment

61

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

Avapritinib

Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed.

DRUG

Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )

Investigators will decide which TKI to use as well as the dosage, frequency, and duration.

Trial Locations (1)

100000

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

CStone Pharmaceuticals

INDUSTRY

NCT05381753 - Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World | Biotech Hunter | Biotech Hunter